Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
Adial Pharmaceuticals (NASDAQ: ADIL) welcomes recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, particularly for Alcohol Use Disorder (AUD). The Senate Appropriations Committee passed a report with a bipartisan 26-3 vote, encouraging the FDA and NIDA to consider alternative endpoints such as reduced cravings and decreased disorder severity.
This development aligns with Adial's clinical strategy for AD04, their lead investigational drug, a serotonin-3 receptor antagonist designed to treat AUD in patients with specific genotypes. The legislative support validates the company's approach of focusing on reducing alcohol intake and cravings rather than complete abstinence.
Adial Pharmaceuticals (NASDAQ: ADIL) accoglie con favore il recente sostegno del Senato USA all'espansione degli endpoint nei trial clinici per i disturbi da uso di sostanze oltre l'astinenza, con particolare riferimento al Disturbo da Uso di Alcol (AUD). Il Comitato per le Approvazioni del Senato ha approvato un rapporto con un voto bipartisan di 26-3, invitando FDA e NIDA a valutare endpoint alternativi come la riduzione delle voglie e la diminuzione della gravità del disturbo.
Questo sviluppo è in linea con la strategia clinica di Adial per AD04, il loro farmaco sperimentale di punta, un antagonista del recettore 5-HT3 studiato per trattare l'AUD in pazienti con specifici genotipi. Il sostegno legislativo conferma l'approccio dell'azienda che punta a ridurre il consumo di alcol e le voglie anziché l'astinenza completa.
Adial Pharmaceuticals (NASDAQ: ADIL) celebra el reciente respaldo del Senado de EE. UU. para ampliar los endpoints en ensayos clínicos de trastornos por consumo de sustancias más allá de la abstinencia, especialmente para el Trastorno por Uso de Alcohol (AUD). El Comité de Asignaciones del Senado aprobó un informe con un voto bipartidista de 26-3, instando a la FDA y al NIDA a considerar endpoints alternativos como la reducción de los ansia y la disminución de la gravedad del trastorno.
Este avance coincide con la estrategia clínica de Adial para AD04, su fármaco candidato principal, un antagonista del receptor de serotonina 3 diseñado para tratar el AUD en pacientes con genotipos específicos. El apoyo legislativo valida el enfoque de la compañía de centrar la atención en reducir el consumo de alcohol y los deseos, en lugar de exigir la abstinencia total.
Adial Pharmaceuticals (NASDAQ: ADIL)는 물질 사용 장애 치료제 임상시험의 평가 지표를 금욕 외의 항목으로 확대하려는 최근 미국 상원의 입법적 지지를 환영합니다. 특히 알코올 사용 장애(AUD)에 관해 상원 배정위원회는 초당파적 26대 3 표결
이런 움직임은 특정 유전자형 환자를 대상으로 한 알코올 사용 장애 치료용 세로토닌-3 수용체 길항제인 주력 임상 후보약 AD04에 대한 Adial의 임상 전략과 일치합니다. 입법적 지지는 완전한 금욕보다는 음주량과 갈망 감소에 중점을 두는 회사의 접근법을 뒷받침합니다.
Adial Pharmaceuticals (NASDAQ: ADIL) se félicite du récent soutien législatif du Sénat américain en faveur de l'élargissement des critères d'évaluation des essais cliniques au-delà de l'abstinence pour les troubles liés à l'usage de substances, en particulier le trouble lié à l'usage d'alcool (AUD). Le comité des crédits du Sénat a adopté un rapport par un vote bipartisan de 26-3, encourageant la FDA et le NIDA à envisager des critères alternatifs tels que la réduction des envies et l'atténuation de la sévérité du trouble.
Cette évolution s'aligne sur la stratégie clinique d'Adial pour AD04, leur principal médicament en développement, un antagoniste des récepteurs de la sérotonine-3 conçu pour traiter l'AUD chez des patients porteurs de génotypes spécifiques. Ce soutien législatif confirme l'approche de la société, axée sur la réduction de la consommation d'alcool et des envies plutôt que sur l'abstinence totale.
Adial Pharmaceuticals (NASDAQ: ADIL) begrüßt die jüngste Unterstützung des US-Senats für die Ausweitung klinischer Endpunkte bei Suchterkrankungen über Abstinenz hinaus, insbesondere beim Alkoholgebrauchsstörung (AUD). Der Haushaltsausschuss des Senats verabschiedete einen Bericht mit einer überparteilichen Stimmenzahl von 26-3 und forderte FDA und NIDA auf, alternative Endpunkte wie verringerte Verlangen und reduzierte Schwere der Störung zu prüfen.
Diese Entwicklung steht im Einklang mit Adials klinischer Strategie für AD04, ihr führendes Prüfpräparat, ein 5-HT3-Rezeptorantagonist zur Behandlung von AUD bei Patienten mit bestimmten Genotypen. Die legislative Unterstützung bestätigt den Ansatz des Unternehmens, den Alkoholkonsum und das Verlangen zu reduzieren statt komplette Abstinenz zu verlangen.
- Senate Appropriations Committee shows strong bipartisan support with 26-3 vote
- Legislative support validates AD04's clinical development strategy
- Potential for easier regulatory pathway for AD04 drug approval
- Alignment with real-world patient recovery patterns could increase market acceptance
- AD04 drug still in clinical-stage development
- No guarantee FDA will implement new endpoints despite Senate encouragement
- Timeline for regulatory changes remains uncertain
Insights
Senate support for expanded AUD endpoints validates Adial's approach for AD04, potentially easing regulatory pathway to approval.
The U.S. Senate's recent move to encourage the FDA to adopt broader clinical trial endpoints for Alcohol Use Disorder (AUD) represents a significant regulatory development for Adial Pharmaceuticals. Currently, the FDA primarily accepts complete abstinence as the gold standard endpoint for AUD treatments, creating an extremely high regulatory hurdle that few candidates can overcome. This appropriations report, which passed committee with strong bipartisan support (26-3), promotes alternative endpoints including reduced cravings, decreased alcohol consumption, and lower disorder severity – precisely the metrics Adial's AD04 drug is designed to address.
This regulatory shift could substantially de-risk Adial's clinical development pathway for AD04, their lead serotonin-3 receptor antagonist. Rather than demonstrating complete abstinence (an all-or-nothing metric), Adial could potentially secure approval by showing meaningful reductions in drinking behavior and cravings in genetically targeted patients. The alignment between Senate guidance and Adial's existing strategy suggests the company has been pursuing a scientifically sound approach that regulators are increasingly willing to accept.
The bipartisan nature of this support indicates a sustainable regulatory direction rather than a temporary political stance. For a small clinical-stage company like Adial, this regulatory tailwind could significantly reduce development costs and timelines while increasing probability of success. However, investors should note that while this creates a more favorable regulatory environment, AD04 must still demonstrate clinical efficacy and safety in upcoming trials before reaching commercialization.
U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory Environment
GLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, including Alcohol Use Disorder (AUD). The U.S. Senate’s move to encourage the FDA to develop new endpoints for AUD, such as reduced cravings, to enhance the regulatory pathway for new pharmaceutical candidates strongly reinforces Adial’s clinical development strategy for AD04, its lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of AUD in individuals with heavy drinking and select genotypes.
The Appropriations report, which recently advanced out of Committee on a bipartisan 26-3 vote, encourages the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA) to support alternative clinical endpoints such as reduced craving, reduced drug or alcohol use, and decreased disorder severity. This forward-thinking perspective validates Adial’s patient-centric approach to AUD treatment and promotes a more supportive regulatory environment for AD04’s continued development. By moving beyond abstinence as the singular measure of success, the new legislative language reflects real-world patient focused recovery patterns and offers an evidence-based path forward for evaluating treatments like AD04. AD04 is intended to help patients reduce alcohol intake and cravings, making it uniquely positioned to benefit from the Committee’s call for more relevant, patient-focused clinical trial endpoints.
“We are encouraged by this legislative momentum, which mirrors the very foundation of our AD04 program,” said Cary Claiborne, CEO of Adial Pharmaceuticals. “Our therapy is designed to reduce cravings and harmful alcohol consumption, rather than enforce an all-or-nothing abstinence model. As the U.S. Senate report makes clear, there is tremendous unmet medical need for new AUD therapies. This legislative directive signals meaningful change and momentum—one that brings the science, patient needs, and regulatory vision into closer alignment.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, being developed for the treatment of Alcohol Use Disorder (AUD). AD04 was recently investigated in a Phase 3 clinical trial ONWARD™ and showed promising results with reduced drinking in patients with AUD, and was well tolerated with no overt safety concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the Committee’s forward-thinking perspective validating Adial’s patient-centric approach to AUD treatment and promoting a more supportive regulatory environment for AD04’s continued development, developing AD04 for the treatment of AUD in individuals with heavy drinking and select genotypes, AD04 helping patients reduce alcohol intake and cravings and being uniquely positioned to benefit from the Committee’s call for more relevant, patient-focused clinical trial endpoints, the legislative directive signaling meaningful change and momentum and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
FAQ
What did the U.S. Senate propose regarding clinical trials for Alcohol Use Disorder (AUD) treatments?
How does the Senate's proposal affect Adial Pharmaceuticals (NASDAQ: ADIL)?
What is Adial Pharmaceuticals' AD04 drug designed to do?
What was the voting result for the Senate Appropriations report supporting new AUD treatment endpoints?
